Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$3.13
-0.3%
$3.31
$2.71
$4.73
$599.49M1.2949,072 shs894,105 shs
Evolus, Inc. stock logo
EOLS
Evolus
$9.20
-1.5%
$9.59
$8.67
$17.82
$593.22M0.97769,980 shs880,966 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.97
-2.6%
$12.74
$6.25
$27.38
$163.27M0.43158,434 shs91,806 shs
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$3.50
-4.1%
$3.26
$1.78
$10.72
$600.08M1.622.10 million shs1.86 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
+0.32%-4.27%-8.99%-0.32%-16.93%
Evolus, Inc. stock logo
EOLS
Evolus
+1.52%-4.01%+0.97%-13.44%-21.84%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+5.30%+7.60%+4.80%-0.89%+107.64%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
+0.27%-2.14%+19.28%+35.69%-58.99%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
2.1523 of 5 stars
3.50.00.00.02.72.50.6
Evolus, Inc. stock logo
EOLS
Evolus
3.9638 of 5 stars
3.50.00.03.52.93.30.6
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.1776 of 5 stars
3.50.01.72.72.72.51.3
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.4061 of 5 stars
3.41.00.00.02.82.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
3.00
Buy$5.5075.72% Upside
Evolus, Inc. stock logo
EOLS
Evolus
3.00
Buy$23.75158.15% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50135.16% Upside
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.83
Moderate Buy$17.67404.76% Upside

Current Analyst Ratings Breakdown

Latest LFVN, ABUS, EOLS, and RLAY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
5/7/2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $10.00
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$6.17M97.16N/AN/A$0.51 per share6.14
Evolus, Inc. stock logo
EOLS
Evolus
$266.27M2.23N/AN/A$0.09 per share102.22
Lifevantage Corporation stock logo
LFVN
Lifevantage
$222.35M0.73$0.91 per share14.33$2.05 per share6.33
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$10.01M59.95N/AN/A$4.65 per share0.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$69.92M-$0.41N/AN/AN/A-1,196.64%-75.51%-55.81%8/7/2025 (Estimated)
Evolus, Inc. stock logo
EOLS
Evolus
-$50.42M-$0.89N/AN/AN/A-20.40%-759.04%-20.14%7/30/2025 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.80N/A4.12%34.67%15.24%8/27/2025 (Estimated)
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$337.71M-$2.23N/AN/AN/AN/A-44.17%-39.53%8/5/2025 (Estimated)

Latest LFVN, ABUS, EOLS, and RLAY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$0.02N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$0.49N/AN/AN/A$0.07 millionN/A
7/30/2025Q2 2025
Evolus, Inc. stock logo
EOLS
Evolus
-$0.09N/AN/AN/A$82.18 millionN/A
5/14/2025Q1 2025
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
5/5/2025Q1 2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$0.50-$0.46+$0.04-$0.46$0.01 million$7.68 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
N/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.39%N/A26.09%3 Years
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/AN/AN/AN/AN/A

Latest LFVN, ABUS, EOLS, and RLAY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
0.04
6.01
6.01
Evolus, Inc. stock logo
EOLS
Evolus
22.00
2.34
2.16
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/A
19.96
19.96

Institutional Ownership

CompanyInstitutional Ownership
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
43.79%
Evolus, Inc. stock logo
EOLS
Evolus
90.69%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
96.98%

Insider Ownership

CompanyInsider Ownership
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
20.30%
Evolus, Inc. stock logo
EOLS
Evolus
5.90%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
4.87%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
90191.53 million152.65 millionOptionable
Evolus, Inc. stock logo
EOLS
Evolus
17064.48 million60.67 millionOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
330171.45 million163.10 millionOptionable

Recent News About These Companies

Relay Therapeutics, Inc. (RLAY) - Yahoo Finance
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arbutus Biopharma stock logo

Arbutus Biopharma NASDAQ:ABUS

$3.13 -0.01 (-0.32%)
Closing price 04:00 PM Eastern
Extended Trading
$3.16 +0.04 (+1.12%)
As of 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Evolus stock logo

Evolus NASDAQ:EOLS

$9.20 -0.14 (-1.50%)
Closing price 04:00 PM Eastern
Extended Trading
$9.21 +0.01 (+0.11%)
As of 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.97 -0.34 (-2.55%)
Closing price 04:00 PM Eastern
Extended Trading
$12.96 -0.01 (-0.04%)
As of 05:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Relay Therapeutics stock logo

Relay Therapeutics NASDAQ:RLAY

$3.50 -0.15 (-4.11%)
Closing price 04:00 PM Eastern
Extended Trading
$3.56 +0.06 (+1.86%)
As of 06:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.